|
Synonyms: BL-B01D1 | BMS-986507 | BMS986507 | Iza-bren®
izalontamab brengitecan is an approved drug
Compound class:
Antibody
Comment: Izalontamab brengitecan (BL-B01D1) is a first-in-class bispecific antibody-drug conjugate (ADC) that is designed to deliver the camptothecin derived topoisomerase I inhibitor Ed-04 payload to tumour cells that express EGFR and HER3 receptor tyrosine kinases. The drug carries of eight toxin molecules per antibody (SI-B001) molecule [7,9]. Peptide sequences for the heavy and light chains of the parental antibody (obtained from the INN record) are claimed in patent US10919977, specifically for the clone named SI-1X6.4 [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Izalontamab brengitecan (BL-B01D1) was evaluated as a clinical candidate for the treatment of heavily pre-treated solid tumours (of epithelial origin), including EGFR-mutated NSCLCs, esophageal squamous cell carcinoma (ESCC) [5], ovarian cancer, and urothelial carcinoma [1]. It was first approved for clinical use by China's NMPA in June 2026, to treat recurrent or metastatic nasopharyngeal carcinoma. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT07502300 | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) | Phase 3 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | ||
| NCT07582315 | A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01) | Phase 3 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | ||
| NCT07640789 | A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) | Phase 3 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | ||
| NCT07648914 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) | Phase 3 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | ||
| NCT05194982 | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor | Phase 1 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | 4,6 | |
| NCT05880706 | A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | 4 | |
| NCT06118333 | A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | Phase 3 Interventional | Sichuan Baili Pharmaceutical Co., Ltd. | Objective response rate, median duration of response and median progression-free survival were all significantly increased by BL-B01D1 treatment compared to chemotherapy. | 10 |